Safety and characterization of the immune response engendered by two combined measles, mumps and rubella vaccines

Vaccine

Volumn 16, Issue 2-3, 1998, Pages 298-304

  Schwarzer, Simone ^a   Reibel, Susanne ^a   Lang, Alois B ^b   Struck, Mark Michael ^b   Finkel, Beatriz ^b   Gerike, Edith ^c   Tischer, Annedore ^c   Gassner, Markus ^d   Glück, Reinhard ^b   Stück, Burghard ^a   Cryz Jr , Stanley J ^b  

^a HUMBOLDT UNIVERSITY   (Germany)

^b Berna Biotech AG   (Switzerland)

^c ROBERT KOCH INSTITUTE   (Germany)

^d Kinderspital ^*  (Switzerland)

Author keywords

Immune response; Measles mumps and rubella vaccines; Safety

Indexed keywords

MEASLES MUMPS RUBELLA VACCINE;

ADOLESCENT; ANTIBODY TITER; ARTICLE; CELLULAR IMMUNITY; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; IMMUNIZATION; IMMUNOFLUORESCENCE; IMMUNOGENICITY; INJECTION SITE; MAJOR CLINICAL STUDY; MEASLES; MEASLES VIRUS; MUMPS; MUMPS VIRUS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RUBELLA; SEROCONVERSION; SWITZERLAND;

ANTIBODIES, VIRAL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEVER; HEMAGGLUTINATION INHIBITION TESTS; HUMANS; INFANT; MEASLES; MEASLES-MUMPS-RUBELLA VACCINE; MORBILLIVIRUS; MUMPS; NEUTRALIZATION TESTS; RUBELLA; RUBELLA VIRUS; RUBULAVIRUS;

EID: 9844226791     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(97)00174-6     Document Type: Article

References (22)

1. 1 Peltola, H., Kurki, T. and Virtanen, M. et al. Rapid effect on endemic measles, mumps and rubella of nationwide vaccination program in Finland. Lancet 1986, 2, 137-139.
2. 2 Edmonson, M.B., Addiss, D.G., McPherson, J.T., Berg, J.L., Circo, S.R. and Davis, J.P. Mild measles and secondary vaccine failure during a sustained outbreak in a highly vaccinated population. Jama 1990, 263, 2467-2471.
3. 3 Cheek, J.E., Baron, R., Atlas, H., Wilson, D.L. and Crider, R.D. Mumps outbreak in a highly vaccinated school population. Archives of Pediatric and Adolescent Medicine 1995, 149, 774-778.
4. 4 Peltola, H., Heinonen, O.P. and Valle, M. et al. The elimination of indigenous measles, mumps and rubella from Finland by a 12-year, two-dose vaccination program. New England Journal of Medicine 1994, 331, 1397-1402.
5. 5 Briss, P.A., Fehrs, L.J., Parker, P.A., Wright, P.F., Sannella, E.C. and Hutcheson, R.H. et al. Sustained transmission of mumps in a highly vaccinated population: assessment of primary vaccine failure or waning vaccine-induced immunity. Journal of Infectious Diseases 1994, 169, 77-82.
6. 6 Ward, B.J., Boulianne, N., Ratnam, S., Guiot, M.C., Couillard, M. and de Serres, G. Cellular immunity in measles vaccine failure: demonstration of measles antigen-specific lymphoproliferative responses despite limited serum antibody production after vaccination. Journal of Infectious Diseases 1995, 172, 1591-1595.
7. 7 Christenson, B. and Böhiger, M. Measles antibody: comparison of longterm vaccination titres, early vaccination titres and naturally acquired immunity to and booster effects on the measles virus. Vaccine 1994, 12, 129-133.
8. 8 Markowitz, L.E. and Katz, S.L., Measles vaccine. In Vaccines, ed. S.A. Plotkin and E.A. Mortimer, Saunders, Philadelphia, 1994, pp. 229-276.
9. 9 Cochi, S.L., Wharton, M. and Plotkin, S.A., Mumps Vaccine. In Vaccines, ed. S.A. Plotkin and E.A. Mortimer, Saunders, Philadelphia, 1994, pp. 277-302.
10. 10 Plotkin, S.A., Rubella vaccine. In Vaccines, ed. S.A. Plotkin and E.A. Mortimer, Saunders, Philadelphia, 1994, pp. 303-336.
11. 11 Gray, J.A. and Burns, S.M., Mumps meningitis following measles, mumps and rubella immunization. Lancet, 1989, i, 98.
12. 12 Miller, E., Goldacre, M., Pugh, S., Colville, A., Farrington, P. and Flower, A. et al. Risk of aseptic meningitis after measles, mumps and rubella vaccine in UK children. Lancet 1993, 341, 979-982.
13. 13 Peltola, H. and Heinonen, O.P., Frequency of the adverse reaction to measles-mumps-rubella vaccine. Lancet, 1986, i, 939-942.
14. 14 Cremer, N.E., Cossen, C.K., Shell, G., Diggs, J., Gallo, D. and Schmidt, N.J., Enzyme immunoassay versus plaque neutralization and other methods for determination of immune status to measles and varicella-zoster viruses and versus complement fixation for serodiagnosis of infections with those viruses. Journal of Clinical Microbiology, 1985, 13, 869-874.
15. 15 Goetz, O. and Peller, P. Antikörper gegen das Mumpsvirus bei Kindern und Erwachsenen. Monatsschrift der Kinderheilkunde 1978, 126, 244-245.
16. 16 Zartarian, M.V., Friedly, G., Peterson, E.M. and de la Maza, L.M. Detection of rubella antibodies by hemagglutination inhibition, indirect fluorescent-antibody test, and enzyme-linked immunosorbent assay. Journal of Clinical Microbiology 1981, 14, 640-645.
17. 17 Kenny, M.T. and Schell, K. Microassay of measles and mumps virus and antibody in VERO cells. Journal of Biological Standardization 1975, 3, 291-306.
18. 18 Davidkin, I., Valle, M. and Julkunen, I. Persistence of anti-mumps virus antibodies after a two-dose MMR vaccination. A nine-year follow-up. Vaccine 1995, 13, 1617-1622.
19. 19 Matson, D.O., Byington, C., Canfield, M., Albrecht, P. and Feigin, R.D. Investigation of a measles outbreak in a fully vaccinated school population including serum studies before and after revaccination. Pediatric Infectious Diseases Journal 1993, 12, 292-299.
20. 20 Expanded programme on immunization. Weekly Epidemiological Records, 1995, 31, 21-228.
21. 21 Miller, E., Hill, A., Morgan-Capner, P., Forsey, T. and Rush, M. Antibodies to measles, mumps and rubella in U.K. children 4 years after vaccination with different MMR vaccines. Vaccine 1995, 13, 799-809.
22. 22 Gassner, M., Hess, U. and Berger, R. Mumps: zur Wirksamkeit einer Zweitimpfung. Schweizerische Medizinische Wochenschrift 1995, 125, 2506-2510.